ATHE ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the ShareCafe Hidden Gems webinar on the following dates/times:

AUSTRALIA PARTICIPANTS:

Date:    Friday, 2 February 2024

Time:    12:30 p.m. AEDT / 9:30 a.m. AWST

UNITED STATES PARTICIPANTS:

Date:    Thursday, 1 February 2024

Time:    5:30 p.m. PT / 8:30 p.m. ET

To access further details of the event and to register at no cost, please click , or copy and paste the following link into your internet browser:

An archived replay will be made available following the event.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at

Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:

Australia

Hannah Howlett



U.S.

Remy Bernarda



+1 (415) 203-6386



EN
29/01/2024

Underlying

ATHEALTERITY THERAPEUTICS LIMITED

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALTERITY THERAPEUTICS LIMITED

 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Repor...

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers...

January 30, 2026 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Prog...

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.  Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable us to advan...

January 21, 2026 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual...

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Bell Potter Healthcare Conference, a virtual event showcasing Australia’s best healthcare companies.  Presentation details AUSTRALIA PARTICIPANTS:Date:Wed...

November 12, 2025 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostat...

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System – Data highlights symptom stability and enhanced efficacy signals in higher dose group – – Analysis offers valuable insights to guide ongoing development and planning of Phase 3 – MELBOURNE, Australia and SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

November 10, 2025 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Repor...

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose levelPositive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced MSA as observed in earlier stage patients in double-blind studyIndependent commercial assessment indicates USD $2.4 billion dollar potential worldwide peak sales opportunity in MSA for ATH434Cash balance on 30 September 2025 of A$54.56M MELBOURNE, Australia and SAN FRANCISCO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Alterity T...

October 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch